Neil Butt

Neil has over 25 year’s experience in the biotechnology industry covering both research and business development. Neil’s industrial experience started in R&D (UK Head of Research for Whatman Bioscience), before joining PA Consulting. Neil then joined Antitope as Head of Business Development and oversaw year on year growth and was eventually sold to Polytherics (with the merged company becoming Abzena).

As Head of Business development, Neil was part of the executive management team that managed the listing on AIM and the acquisition of two US companies. On leaving Abzena, Neil joined IONTAS and established the company as the principal service provider for mammalian display, a novel platform or identifying therapeutic antibodies. Neil was on both the executive management team and board of IONTAS which managed the acquisition of IONTAS by FairJourney Biologics in May 2020.​